支持秘鲁逐步淘汰结核病治疗类别 II 方案的更多证据。
Additional evidence to support the phasing-out of treatment category II regimen for pulmonary tuberculosis in Peru.
机构信息
Instituto de Medicina Tropical Alexander von Humboldt, Universidad Peruana Cayetano Heredia, Lima, Peru.
出版信息
Trans R Soc Trop Med Hyg. 2012 Aug;106(8):508-10. doi: 10.1016/j.trstmh.2012.05.008. Epub 2012 Jun 26.
The effectiveness of the World Health Organization's (WHO) treatment category II regimen for tuberculosis in 124 patients was compared to that of 1147 patients receiving treatment category I in Lima, Peru following WHO's guidelines. Drug susceptibility test was available for 85% of patients. Prevalence of multi drug resistance and streptomycin resistance were 5.1% and 20.7%, respectively. Overall cure rate for regimen II was lower than that of regimen I: 67.8% (95% CI: 58.9-75.6.) vs 77.8% (95% CI: 75.3-80.2), p=0.014. Multi-drug resistance exerted a profound effect on cure rates in both regimens. Our results support the phasing-out of treatment category II regimen in Peru.
将世界卫生组织（WHO）的结核病治疗类别 II 方案在 124 名患者中的有效性与利马 1147 名接受符合世卫组织指南的类别 I 治疗的患者进行了比较。对 85%的患者进行了药物敏感性测试。耐多药和链霉素耐药的患病率分别为 5.1%和 20.7%。方案 II 的总体治愈率低于方案 I：67.8%（95%CI：58.9-75.6）与 77.8%（95%CI：75.3-80.2），p=0.014。多药耐药对两种方案的治愈率都有深远影响。我们的结果支持在秘鲁逐步淘汰治疗类别 II 方案。
Zotero 插件